Extracellular Vesicles for Ventricular Tachycardia
Grant Award Details
Grant Type:
Grant Number:
CLIN1-14874
Investigator(s):
Disease Focus:
Human Stem Cell Use:
Award Value:
$5,999,441
Status:
Pre-Active
Grant Application Details
Application Title:
Extracellular Vesicles for Ventricular Tachycardia
Public Abstract:
Therapeutic Candidate or Device
CSSHI-2003 (extracellular vesibles derived from cardiohsphere derived cells)
Indication
Patients afflicted with recurrent fast and irregular heart beating (a.k.a. ventricular tachycardia).
Therapeutic Mechanism
CSHHI-2003 (CDC exosomes) are lipid vesicles filled with bioactive materials that have anti-inflammatory, anti-fibrotic, and regenerative properties. Decreasing the fibrosis in the heart can decrease the incidence of fast and irregular heart beating (a.k.a. ventricular tachycardia) in patients with cardiomyopathy.
Unmet Medical Need
Ventricular tachycardia (VT) is a rapid heart rhythm from the ventricles. Current therapies lack effectiveness, have side effects, and lack consensus. Non-destructive fibrosis-reducing therapy can improve outcomes in some patients with recurrent VT.
Project Objective
Filling of IND and design of Phase 1 trial
Major Proposed Activities
CSSHI-2003 (extracellular vesibles derived from cardiohsphere derived cells)
Indication
Patients afflicted with recurrent fast and irregular heart beating (a.k.a. ventricular tachycardia).
Therapeutic Mechanism
CSHHI-2003 (CDC exosomes) are lipid vesicles filled with bioactive materials that have anti-inflammatory, anti-fibrotic, and regenerative properties. Decreasing the fibrosis in the heart can decrease the incidence of fast and irregular heart beating (a.k.a. ventricular tachycardia) in patients with cardiomyopathy.
Unmet Medical Need
Ventricular tachycardia (VT) is a rapid heart rhythm from the ventricles. Current therapies lack effectiveness, have side effects, and lack consensus. Non-destructive fibrosis-reducing therapy can improve outcomes in some patients with recurrent VT.
Project Objective
Filling of IND and design of Phase 1 trial
Major Proposed Activities
- Manufacture product (CSSHI-23) for the proposed study
- Completion of prelclinical safety studies
- Completion of preclinical efficacy studies
Statement of Benefit to California:
A non-invasive cell-derived therapy for ventricular tachycardia offers significant benefits to California. It provides a safer alternative to invasive procedures, reducing risks and complications. This enhances healthcare by lowering costs, improving quality of life, and promoting accessible and effective treatment. California fosters a healthier population, ensuring a brighter future for residents.